MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD9 Codes        Equipment        Hospitals        Drugs        More..
  

Useful Websites

Global Translations
Medical and Clinical Translation

specialistinfo.com
Details of over 40,000 UK Specialists and over 42,000 GPs

Global RPH
medical software

Doctors Lounge
Ask a Doctor and Disease Information

Health News
from Medical News Today.

MRCP 1 Revision
123 Doc medical courses for junior doctors.

CoreyNahman
pharmaceutical news daily

Hospital Search
Worldwide hospital database, search by country or keyword.

Metric Conversions
The Converter Site - unit conversion tool.
headlines news headlines   email email to a friend   printer printer friendly   newsletter sign up to newsletter  

Part D Negotiation Will Save Medicare And Seniors Billions

Main Category: Medicare / Medicaid / SCHIP
Also Included In: Seniors / Aging
Article Date: 30 Oct 2009

An analysis by the National Committee to Preserve Social Security and Medicare shows that health care reform proposals, which allow Medicare to negotiate the lowest drug prices for beneficiaries in Part D, would save $24 billion each year. That savings would be more than enough to close the Part D coverage gap known as the "doughnut hole" and address other deficiencies in the Part D plan.

Currently, Medicare is prohibited from negotiating lower drug costs for beneficiaries in Part D. If that ban was removed, Medicare could bargain for lower costs just as Medicaid and the Veteran's Administration do now. The National Committee has compared the lowest prices obtained by private Part D plans for the top ten prescribed drugs with prices obtained by the VA for the same drugs. The VA savings were substantially greater for all ten drugs; Amlodipine Besylate, Furosemide, Lipitor, Lisinopril, Hydrocodone, Atenolol, Levothyroxine NA, Hydrochlorothiazide, Metroprolol Tartrate, Metformin HCL. For example:

- Part D plans spend 99.7% more than the VA for the generic form of the hypertension drug Norvasc (amlodipine besylate).
- Part D plans spend 64% more than the VA for the generic form of the most commonly filled Part D prescription, Lasix (furosemide).
- Part D plans spend 28.5% more for the heart disease drug, Lipitor, than the VA.

"This report shows that allowing price negotiation in Part D is a win-win proposition for Medicare and seniors because it shifts the focus back to providing the best prices to government and its beneficiaries rather than boosting industry profits. It's clear we can find health care reform savings in Medicare without cutting benefits; however, drug makers and insurers have a vested interest in protecting the status quo. Reforming Part D must be a part of any final health care bill and allowing price negotiation is a critical part of that reform."...Barbara B. Kennelly, President/CEO

The full report is available online here.

Source
The National Committee

Original article posted on Medical News Today.
Articles not to be reproduced without permission of Medical News Today

Medical News Today publishes the latest health news and health videos for consumers and health professionals. It has a searchable archive of over 100,000 health news articles.





For any corrections of factual information, or to contact the editors please use our feedback form.
Send your press releases to








free web search box


pda medical dictionary
pda software - $15

PDA Medical Dictionary

only $15

Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...

>> Click here for more on the PDA Medical Dictionary <<




add to google

Add our searches to your Google homepage.

Add to Google

The 60 seconds challenge: Add these searches to your Google homepage within 60 seconds - simply click here and follow these instructions


Receive the latest medical news on your Google homepage.

Add to Google

The 60 seconds challenge: Receive the latest medical news on your Google homepage within 60 seconds - simply click here and follow these instructions





Privacy Policy   |    Disclaimer      

MediLexicon International Ltd, UK Office: +44 (0) 1625 415 347
MediLexicon International Ltd © 2009 All rights reserved.